金吾财讯 | 拜玛林制药（BMRN）宣布与Ascendis PharmaA/S达成具有约束力的全球专利和解协议，全面解决双方围绕Ascendis旗下软骨发育不全治疗药物Yuviwel产生的所有专利及相关诉讼争议。根据协议条款，Ascendis将向拜玛林制药支付基于Yuviwel净销售额的特许权使用费：其中美国市场分成比例为20%（追溯至首次商业化销售），欧洲联盟、巴西及韩国市场的分成比例为18%，支付期限将持续至2030年5月。作为回报，拜玛林制药将向Ascendis授予针对Yuviwel所有现行及潜在适应症（包括软骨发育不全和伪软骨发育不全）以及联合用药方案的专利许可，并撤回在美国国际贸易委员会（ITC）发起的337调查以及在德国、丹麦、巴西、韩国和美国加州北区法院挂牌的诉讼。行业分析指出，该协议不仅认可了拜玛林制药在C型利钠肽（CNP）技术及重磅药物VOXZOGO研发上的先驱地位，也为其带来了长达数年的稳定高毛利现金流，同时避免了跨国诉讼带来的高额法务开支与不确定性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.